DNLI

Over the past six months, Denali Therapeutics' stock (DNLI) decreased by 15.44% over the last month and 31.39% over the last three months, but showed a year-to-date increase of 13.08% and a one-year increase of 19.30%. Its 52-week high was $27.30 and its 12-month low was $13.75. Key events included the FDA approval of AVLAYAH™ for Hunter syndrome in March 2026, the sale of a Rare Pediatric Disease Priority Review Voucher for $195 million in June 2026, and the reporting of Q2 2026 financial results in August 2026, which showed AVLAYAH net product revenue exceeding expectations but a wider-than-expected adjusted loss per share. In August 2026, B. Riley Financial raised its price target to $35.00 and maintained a 'buy' rating. Denali participated in major healthcare conferences in September 2026. In October 2026, Wall Street Zen downgraded the stock to 'sell' due to the wider quarterly loss, although other analysts maintained a 'Moderate Buy' consensus with an average target price of $35.85.